Zyn is significantly lower in harmful chemicals than dip. Traditional moist snuff contains at least 27 measurable harmful compounds, including cancer-causing nitrosamines and heavy metals, while Zyn contains none of the nitrosamines or cancer-linked hydrocarbons found in tobacco products. That chemical gap is large enough that the FDA authorized 20 Zyn products for marketing in 2025, specifically noting they “pose lower risk of cancer and other serious health conditions” than cigarettes, moist snuff, and snus. That said, Zyn still delivers nicotine, and nicotine carries its own health effects.
What’s Actually in Each Product
The core difference between Zyn and dip is that dip is made from cured tobacco leaf, while Zyn uses synthetic or extracted nicotine with no tobacco plant material. That distinction matters because the tobacco leaf is where the most dangerous chemicals come from.
Moist snuff contains six of the seven tested polycyclic aromatic hydrocarbons (compounds linked to cancer) and seven of ten tested nitrosamines, including NNN and NNK, two of the most potent carcinogens in smokeless tobacco. A single pouch of spit-free snus, which is already considered cleaner than American dip, can contain up to 1,190 nanograms of NNN and 120 nanograms of NNK. Zyn pouches max out at roughly 13 nanograms of NNN and 5.4 nanograms of NNK, putting them closer to nicotine gum than to any tobacco product. Both dip and Zyn contain trace heavy metals like chromium and nickel, but dip adds arsenic, cadmium, lead, selenium, and a radioactive polonium isotope to the mix.
Cancer Risk Is Not the Same
Nicotine itself is not a carcinogen. The cancer risk from dip comes from the nitrosamines, hydrocarbons, and other byproducts of tobacco processing. Since Zyn contains none of the hydrocarbons and only trace-level nitrosamines comparable to nicotine replacement products like gum and lozenges, the carcinogenic profile is dramatically different. The FDA’s review confirmed this gap when it found that Zyn’s harmful constituents are “substantially lower” than those in cigarettes and most smokeless tobacco products.
Long-term users of moist snuff have well-documented rates of leukoplakia (white patches inside the mouth that can become precancerous) and elevated oral cancer risk. No equivalent data exists for Zyn because the product category is too new. But the absence of known carcinogens in meaningful quantities makes a direct cancer comparison difficult to draw in dip’s favor.
What Zyn Still Does to Your Mouth
Even without tobacco, placing a pouch between your gum and lip for extended periods is likely to cause gum recession near the spot where you hold it. This is a known side effect of Swedish snus, and dental researchers expect similar effects from nicotine pouches given the identical method of use. No published studies have directly measured gum damage from Zyn yet, but the mechanical irritation and nicotine exposure to gum tissue are real concerns for regular users.
One clear advantage for Zyn is tooth staining. In lab testing, nicotine pouches caused almost no color change to teeth compared to a saliva control. Smokeless tobacco caused roughly 19 times more staining than nicotine pouches did. Both products stained far less than cigarettes, but the gap between Zyn and dip is substantial enough to notice in daily life.
Nicotine Delivery Is Similar
If you’re wondering whether Zyn gives you less of a nicotine hit than dip, the pharmacokinetics are actually quite close. Both products take about 30 to 40 minutes to reach peak nicotine levels in the blood. One study found nicotine pouches peaked at 32 to 34 minutes, while moist snuff peaked at around 34 minutes. Another found both in the 36 to 42 minute range. This is much slower than a cigarette, which peaks in 5 to 8 minutes, but the overall nicotine absorption between Zyn and dip is comparable.
Zyn pouches range in pH from about 6.9 to 10.2 across the product line, with higher pH meaning more “freebase” nicotine that absorbs faster through your gum tissue. Total nicotine per pouch ranges from 1.3 to 6.1 milligrams. That wide range means a high-strength Zyn can deliver a nicotine experience similar to a pinch of dip, while a low-strength pouch delivers noticeably less.
Heart and Blood Pressure Effects
This is where the products converge. Nicotine, regardless of its source, raises blood pressure and heart rate within minutes of use. A 2024 study found that nicotine pouches containing 6 milligrams of nicotine increased both systolic and diastolic blood pressure within 6 to 20 minutes, though levels returned to baseline within 40 minutes even with 30-milligram pouches.
When people quit nicotine pouches or snus entirely, their resting heart rate drops by nearly 6 beats per minute in the first week. That gives you a sense of the ongoing cardiovascular burden that comes with regular use of either product. Direct long-term cardiovascular data on nicotine pouches is essentially nonexistent right now. The known effects of chronic nicotine exposure, including increased blood pressure, arterial stiffness, and potential links to diabetes risk, apply equally to Zyn and dip because they stem from nicotine itself rather than the tobacco-specific chemicals.
What the FDA Authorization Actually Means
The FDA’s 2025 marketing authorization for Zyn is significant but often misunderstood. The agency found that these specific products meet a “public health standard,” meaning the benefits to adults switching from cigarettes or smokeless tobacco outweigh the risks, including risks to youth who might pick them up. The authorization does not mean Zyn is safe, and the FDA explicitly said so. It also does not allow the company to market Zyn as “reduced risk” compared to other products. That would require a separate application that has not been filed or granted.
What the authorization does confirm is that the FDA reviewed the chemical composition and found substantially lower levels of harmful compounds than in dip. It also confirmed that a meaningful number of adult tobacco users in company studies completely switched from cigarettes or smokeless tobacco to Zyn, which the agency considered a population-level benefit.
The Bottom Line on Switching
If you currently use dip and are choosing between the two, Zyn exposes you to far fewer carcinogens, causes dramatically less tooth staining, and eliminates your exposure to the tobacco-specific compounds most strongly linked to oral cancer. The nicotine delivery is similar, so the switch does not necessarily reduce your nicotine dependence. Your heart and blood vessels face roughly the same short-term stress from either product, and nobody yet knows the 20-year cardiovascular picture for nicotine pouch users. If you don’t currently use either product, neither one is a risk-free choice. Nicotine is addictive regardless of its packaging, and the long-term consequences of daily pouch use remain an open question.